Rheumatoid arthritis (in combination with methotrexate)
which has not responded to methotrexate alone
(specialist use only)
▶BY SUBCUTANEOUS INJECTION
▶Adult: 100 mg once daily
Cryopyrin-associated periodic syndromes (specialist use
only)
▶BY SUBCUTANEOUS INJECTION
▶Adult: 1–2 mg/kg daily, for severe cryopyrin-associated
periodic syndromes, usual maintenance is 3–4 mg/kg
daily, up to a maximum of 8 mg/kg daily
Still’s disease (specialist use only)
▶BY SUBCUTANEOUS INJECTION
▶Adult (body-weight up to 49 kg): 1–2 mg/kg daily
▶Adult (body-weight 50 kg and above): 100 mg daily
PDF page 1181
Active infection. neutropenia
(absolute neutrophil count less than 1.5 6 109/litre)—do
not initiate. pre-existing malignancy
PDF page 1181
Elderly. history of asthma (increased risk of
serious infection). history of recurrent infection.
predisposition to infection
PDF page 1181
Manufacturer advises
patients should be screened for latent tuberculosis and
viral hepatitis prior to initiation of treatment.
PDF page 1182
▶When used for Cryopyrin-associated periodic syndromes or Still’s
disease The manufacturer of Kineret ® has provided a Guide
for Healthcare Professionals.
PDF page 1182
Scottish Medicines Consortium (SMC) decisions
SMC No. 05/02
The Scottish Medicines Consortium has advised (November
2002) that anakinra (Kineret ®) is not recommended for the
treatment of rheumatoid arthritis within NHS Scotland.
SMC No. SMC2104
The Scottish Medicines Consortium has advised (October
2018) that anakinra (Kineret ®) is accepted for use within
NHS Scotland for the treatment of Still’s disease, as
monotherapy or in combination with other anti-
inflammatory drugs and disease-modifying anti-rheumatic
drugs.
PDF page 1182
